Investor Alert: Approximately 72 Hours Remain; Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Large Financial Interests Of Important Deadline In Lawsuit Against Metabolix, Inc.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until April 17, 2012 to file lead plaintiff applications in a securities class action lawsuit against Metabolix, Inc. (Nasdaq: MBLX), if they purchased the Company’s common stock during the period March 10, 2010 and January 12, 2012, inclusive (the "Class Period"). The action has been filed in the United States District Court for the District of Massachusetts.
What You May Do
If you purchased shares of Metabolix and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, e-mail or call KSF Managing Partner, Lewis Kahn ( firstname.lastname@example.org), toll free, 877-515-1850, or via cell phone any time at 504-301-7900, or KSF Director of Client Relations, Neil Rothstein, Esq. ( email@example.com), toll free at 877-694-9510, or via cell phone any time at 330-860-4092. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 17, 2012.
About Kahn Swick & Foti, LLCKSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities class action and shareholder derivative litigation with offices in New York and Louisiana. KSF's lawyers have significant experience litigating complex securities class actions nationwide on behalf of both institutional and individual shareholders. To learn more about KSF, you may visit www.ksfcounsel.com.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts